TrialDiabetes care2007

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

Tina Vilsbøll et al.PubMed ↗Publisher ↗

No numbers read from the abstract.